Atropine affects neural activity in the inner retina and photoreceptors.
In practice, initiating 0.01% atropine treatment for a child would inevitably delay implementation of an effective dose. This is particularly problematic in the early stages of myopia development when progression is most rapid. Since the sight‐threatening complications of myopia result primarily from excessive tissue stretch, effective slowing of eye growth would significantly ameliorate the risks and consequently help reduce the burden of future sight loss.
We investigated the site and mode of action of atropine eye drops and showed that atropine acts in the inner layers of the peripheral retina to affect neuronal responses to myopic defocus.
Despite the global use of atropine in myopia control, the mechanism by which atropine acts to inhibit the progression of myopia is still unclear. This study investigates the effect of atropine on the human global flash mfERG under conditions of …